ReviewFrontiers in immunology2016
Inflammation Meets Metabolic Disease: Gut Feeling Mediated by GLP-1.
Review in Frontiers in immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed, 1 synthesis or guideline pooled it, 120 citations in OpenAlex.
- Association between GLP-1 receptor agonists as a class and colorectal cancer risk: a meta-analysis of retrospective cohort studies.BMC gastroenterology · 2025Pooled it
- Modulation of GLP-1 Levels by a Genetic Variant That Regulates the Cardiovascular Effects of Intensive Glycemic Control in ACCORD.Diabetes care · 2018Trial
- Beyond Weight Loss: Gut Microenvironment Modulation to Enhance Cardiometabolic Outcomes and Long-Term Adherence During Incretin-Based Therapy.Journal of clinical medicine · 2026Review
- Lipopolysaccharide-induced alterations in barrier integrity and inflammatory signaling in porcine small intestinal organoids.PloS one · 2026Article
- A Multidisciplinary Perspective on Semaglutide Treatment and Medical Nutrition Therapy in Obesity Management.Current obesity reports · 2025Review
- Engineered GLP-1R-targeting nanoplatforms: multimodal therapeutics in human diseases.Journal of nanobiotechnology · 2025Review
- The pyrethroid insecticide deltamethrin disrupts neuropeptide and monoamine signaling pathways in the gastrointestinal tract.Toxicological sciences : an official journal of the Society of Toxicology · 2025Article
- Unravelling the Relationship Between Obesity and Inflammatory Bowel Disease.Inflammatory bowel diseases · 2025Review
- Tolerability and Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Inflammatory Bowel Disease.Digestive diseases and sciences · 2025Article
- Pathological Alterations in Human Blood Microbiome-An Updated Review.International journal of molecular sciences · 2025Review
- Relevance of Glucagon-Like Peptide 1 (GLP-1) in Inflammatory Bowel Diseases: A Narrative Review.Current issues in molecular biology · 2025Review
- What Doesn't Kill You Makes You Stronger? Examining Relationships Between Early-Life Stress, Later-Life Inflammation and Mortality Risk in Skeletal Remains.American journal of biological anthropology · 2025Article
- GLP-1 receptor agonists in IBD: exploring the crossroads of metabolism and inflammation.Frontiers in immunology · 2025Review
- Article
- Peroxisomal cholesterol metabolism regulates yap-signaling, which maintains intestinal epithelial barrier function and is altered in Crohn's disease.Cell death & disease · 2024Article
- The Relationship of Adherence to the Mediterranean Diet with Disease Activity and Quality of Life in Crohn's Disease Patients.Medicina (Kaunas, Lithuania) · 2024Article
- NLRP3 Inflammasome and Gut Dysbiosis Linking Diabetes Mellitus and Inflammatory Bowel Disease.Archives of internal medicine research · 2024Article
- Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications.Therapeutic advances in endocrinology and metabolism · 2024Review
- Alteration of stool pH and its association with biomarkers of gut enteropathy among slum-dwelling women of reproductive age in Bangladesh.BMC women's health · 2023Article
- The Role of Cortisol in Chronic Stress, Neurodegenerative Diseases, and Psychological Disorders.Cells · 2023Review
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic diseases, such as obesity and diabetes, cardiovascular, and inflammatory bowel diseases (IBD) share common features in their pathology. Metabolic disorders exhibit strong inflammatory underpinnings and vice versa, inflammation is associated with metabolic alterations. Next to cytokines and cellular stress pathways, such as the unfolded protein response (UPR), alterations in the enteroendocrine system are intersections of various pathologies. Enteroendocrine cells (EEC) have been studied extensively for their ability to regulate gastrointestinal motility, secretion, and insulin release by release of peptide hormones. In particular, the L-cell-derived incretin hormone glucagon-like peptide 1 (GLP-1) has gained enormous attention due to its insulinotropic action and relevance in the treatment of type 2 diabetes (T2D). Yet, accumulating data indicate a critical role for EEC and in particular for GLP-1 in metabolic adaptation and in orchestrating immune responses beyond blood glucose control. EEC sense the lamina propria and luminal environment, including the microbiota via receptors and transporters. Subsequently, mediating signals by secreting hormones and cytokines, EEC can be considered as integrators of metabolic and inflammatory signaling. This review focuses on L cell and GLP-1 functions in the context of metabolic and inflammatory diseases. The effects of incretin-based therapies on metabolism and immune system are discussed and the interrelation and common features of metabolic and immune-mediated disorders are highlighted. Moreover, it presents data on the impact of inflammation, in particular of IBD on EEC and discusses the potential role of the microbiota as link between nutrients, metabolism, immunity, and disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.